Cui Hui Juan
China-Japan Friendship Hospital · Integrative Medicine Oncology Department · Beijing
1):,, NCCN.;. (2) 、: 10,,, “ ” TKI, “ ” TKI..
《 》, 《 》.::1985,;2002;2012.2009 12.2012 9 --11.:1985 、 、 、.2009 12 2017 12.:1.: PLA2G4A IL-6/STAT3 “ ”,2019/01-2022/12,:8187151262;2.: EGFRIs,2012/07—2015/09,:Z121107001012072;3.: “ ” EGFRIs 、 、,2015/07-2018/09,:Z151100004015168;4.: “ ” 、 、,2018/01-2020-12,: 2018-2-4065;5.: ( 2 ),2007-2010,:SF-2007-1-07;6.: “ ”,2020/01-2021/06.: 150, 10 SCI. 1.Serumhepaticenzymemanifestationsinpatientswithsevereacuterespiratorysyndrome:RetrospectiveanalysisWorldGastroenterol2004;10(11):1652-1655(SCI 2.532) 2.. 2005,5(8):613–615 3.,,.,,2009,29(3):346-347 4..,,2011,52(10):821-823 5.,,,. 120.,2013,20(4):14-17. 6..,,2015,56(16):1401-1405 7.,,,,,,,2017,27(1):17-21 8.,,,,. [J].,2017,37(2):149-154. 9.Yanmeipeng,HuijuanCui,ZheLiu,etal.ApatinibtocombatEGFRTKIresistanceinanadvancednonsmallcelllungcancerpatientwithunknownEGFRstatus:acasereport[J].OncoTargetsandTherapy,2017,10:2289–2295.(IF:2.272) 10.PengYM,DuanH,ZhangJ,SunC,ZhangX,ShenW,ZhengS,TanK,JiangX,LiJ,CuiHJ.ApplicationofZizaoYangrongGranulesforTreatingTargetedDrugsRelatedSkinXerosis:ARandomizedDouble-BlindedControlledStudy.IntegrCancerTher.2020,19:1534735420924832.IF:2.379 11.ZhengShuyue,DuanHua,CuiHuijuan.RecurrenceofImmuneRelatedAdverseEventsafterImmuneCheckpointInhibitorsRechallenge.JAMAOncol.2020Nov;6(11):1813.( 24.799) 12.,,,,,,,,,,...2021;41(03):352-7: 2002, 30, 5.: 3,;;; 、 、.